Myopia
Conditions
Brief summary
The objective of this clinical trial is to evaluate the safety and effectiveness of the Carl Zeiss Meditec VisuMax™ Femtosecond Laser lenticule removal procedure for the reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE (Manifest Refractive Spherical Equivalent) ≤ -8.25 D.
Detailed description
This is a prospective multi-center clinical trial in which a total of 360 eyes of consecutive subjects will be enrolled, treated with the VisuMax™ Femtosecond Laser, and followed for a 12-month period. The study will be conducted at up to 8 clinical sites. Enrollment will be phased such that 100 eyes will be initially enrolled and followed. When 50 of the initial eyes have reached the 3-month follow-up exam, an interim clinical study report will be submitted to FDA along with a request to continue enrollment up to 360 eyes. Subjects will be screened for eligibility, and informed consent will be obtained from those who meet screening criteria and are interested in participating in the study. Eligible subjects will be examined preoperatively to obtain a medical history and to establish a baseline ocular condition. Baseline and postoperative measurements will include manifest refraction, cycloplegic refraction, distance visual acuity (best corrected and uncorrected), slit-lamp examination, fundus examination, corneal topography, central corneal pachymetry, mesopic pupil measurement, wavefront analysis, mesopic contrast sensitivity, and intraocular pressure (IOP).
Interventions
DEVICETreatment with the VisuMax™ Femtosecond Laser
The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Sponsors
Carl Zeiss Meditec, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male and female subjects age 22 years of age and older; * Spherical myopia from ≥ -1.00 D to ≤ -8.00 D, with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D in the eye to be treated; * A stable refraction for the past year, as demonstrated by a change in MRSE of ≤ 0.50 D in the eye to be treated; * A difference between cycloplegic and manifest refractions of \< 0.75 D spherical equivalent in the eye to be treated; * UCVA worse than 20/40 in the eye to be treated; * BSCVA at least 20/20 in the eye to be treated; * Discontinue use of contact lenses for at least 2 weeks (for hard lenses) or 3 days (for soft lenses) prior to the preoperative examination, and through the day of surgery; * All contact lens wearers must demonstrate a stable refraction (within ±0.5 D), as determined by MRSE, on two consecutive examinations at least 1 week apart, in the eye to be treated; * Central corneal thickness of at least 500 microns in the eye to be treated; * Willing and able to return for scheduled follow-up examinations; * Able to provide written informed consent and follow study instructions in English.
Exclusion criteria
* Mesopic pupil diameter \> 8.0 mm; * Cylinder \> -0.50 D; * Treatment depth is less than 250 microns from the corneal endothelium; * Eye to be treated is targeted for monovision; * Fellow eye has BSCVA worse than 20/40; * Abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal degeneration in either eye; * History of or current anterior segment pathology, including cataracts in the eye to be treated; * Clinically significant dry eye syndrome unresolved by treatment in either eye; * Residual, recurrent, active ocular or uncontrolled eyelid disease, corneal scars or other corneal abnormality such as recurrent corneal erosion or severe basement membrane disease in the eye to be treated; * Ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect) in either eye; * Irregular or unstable (distorted/not clear) corneal mires on central keratometry images in either eye; * History of ocular herpes zoster or herpes simplex keratitis; * Deep orbits, strong blink, anxiety, pterygium, or any other finding suggesting difficulty in achieving or maintaining suction; * Difficulty following directions or unable to fixate; * Previous intraocular or corneal surgery of any kind in the eye to be treated, including any type of surgery for either refractive or therapeutic purposes; * History of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative IOP \> 21 mmHg in either eye; * History of diabetes, diagnosed autoimmune disease, connective tissue disease or clinically significant atopic syndrome; * Immunocompromised or requires chronic systemic corticosteroids or other immunosuppressive therapy that may affect wound healing; * History of known sensitivity to planned study medications; * Participating in any other ophthalmic drug or device clinical trial during the time of this clinical investigation; * Pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness- Predictability of Participant Refractive Outcomes | 12 months | Number of participants with a decrease in manifest refraction spherical equivalent (MRSE) to within ± 1.00 D and ± 0.50 D of the intended refractive outcome at the point at which stability is first reached. The MRSE is the amount of prescription needed to obtain your best corrected vision as compared to your preoperative best corrected vision. A minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome. |
| Effectiveness- Number of Participants With an Improvement in UCVA Following Treatment | 12 month | Number of participants with uncorrected visual acuity (UCVA) of 20/40 or better at the point of stability. .This is vision without any form of prescription. A target of 85% of participants is required. |
| Stability Criteria- Number of Participants With a Change Between Visits Within 1.00 Diopter (D) | 6 months | Number of participants with a change in postoperative refraction within 1.00 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study. |
| Safety- Number of Participants With a Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA) | 12 months | 1. Number of participants with worse than 20/40 visual acuity with a preoperative BSCVA (Best Spectacle Corrected Visual Acuity) 20/20 or better. Target is less than 1% of study participants. 2. Less than 5% of participants with BCVA loss ≥ 2 lines |
| Safety- Number of Participants With Induced Manifest Refractive Astigmatism | 12 months | Number of participants with an increase of astigmatism of greater than 2.00 D cylinder from the preoperative values. Target is less than 5% of participants. |
| Safety- Number of Participants With Adverse Events | 12 months | Number of participants for each type of adverse event. Target of less than 1% of participants for each type of adverse event. |
| Safety- Contrast Sensitivity of Participants | 12 months | Number of participants who increased, remained the same, and decreased in contrast sensitivity. There are 4 different frequencies (1.5, 3.0, 6.0, and 12.0) which will be tested and are more difficult to detect as the frequency number increases. |
| Stability Criteria- Number of Participants With a Change Between Visits Within 0.50 Diopter (D) | 6 months | Number of participants with a change in postoperative refraction within 0.50 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety- Participant Symptoms | 12 months | A standardized quality of vision (QoV) questionnaire was used in the study. A score is generated and was used to compare the results from baseline to the 12 month visit. Number of participants who improved, stayed the same, or worsened with regards to the frequency, severity, and bothersomeness of symptoms are reported. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJon Dishler, M.D.
Dishler Laser Institute
PRINCIPAL_INVESTIGATORJohn Doane, M.D.
Discover Vision Centers
PRINCIPAL_INVESTIGATORVance Thompson, M.D.
Vance Thompson Vision Clinic, Prof., LLC
PRINCIPAL_INVESTIGATORWilliam Culbertson, M.D.
Bascom Palmer Eye Institute
PRINCIPAL_INVESTIGATORSonia Yoo, M.D.
Bascom Palmer Eye Institute
PRINCIPAL_INVESTIGATORJohn Vukich, M.D.
Davis Duehr Dean
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment of Myopia The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
Treatment with the VisuMax™ Femtosecond Laser: The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D. | 336 |
| Total | 336 |
Baseline characteristics
| Characteristic | Treatment of Myopia |
|---|---|
| Age, Continuous | 33.33 years STANDARD_DEVIATION 7.9 |
| Race/Ethnicity, Customized asian | 6 Participants |
| Race/Ethnicity, Customized black | 10 Participants |
| Race/Ethnicity, Customized other | 11 Participants |
| Race/Ethnicity, Customized white | 309 Participants |
| Sex: Female, Male Female | 196 Participants |
| Sex: Female, Male Male | 140 Participants |
| Surgical Eye left | 184 Participants |
| Surgical Eye right | 152 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 336 |
| other Total, other adverse events | 14 / 336 |
| serious Total, serious adverse events | 0 / 336 |
Outcome results
Primary
Effectiveness- Improvement in UCVA Following Treatment
Number of participants with uncorrected visual acuity (UCVA) of 20/40 or better at the point of stability. .This is vision without any form of prescription. A target of 85% of participants is required.
Time frame: 12 month
Population: The number reflected at the 12 month visit is the effectiveness population.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment of Myopia | Effectiveness- Improvement in UCVA Following Treatment | 309 Participants |
Primary
Effectiveness- Predictability
Number of participants with a decrease in manifest refraction spherical equivalent (MRSE) to within ± 1.00 D and ± 0.50 D of the intended refractive outcome at the point at which stability is first reached. The MRSE is the amount of prescription needed to obtain your best corrected vision as compared to your preoperative best corrected vision. A minimum of 75% of eyes should have an achieved refraction within ± 1.00 D of the intended outcome, and at least 50% of eyes should be within ± 0.50 D of the intended outcome.
Time frame: 12 months
Population: The number reflected at the 12 month visit is the effectiveness population.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment of Myopia | Effectiveness- Predictability | MRSE, Attempted vs. Achieved, ±0.50 D | 291 Participants |
| Treatment of Myopia | Effectiveness- Predictability | MRSE, Attempted vs. Achieved, ±1.00 D | 306 Participants |
Primary
Safety- Adverse Events
Number of participants for each type of adverse event. Target of less than 1% of participants for each type of adverse event.
Time frame: 12 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment of Myopia | Safety- Adverse Events | Retinal vasculitis | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Carcinoma in situ, conjunctival | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Decrease in BSCVA of ≥ 2 lines (≥10 letters) not d | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Conjunctivitis, allergic | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Conjunctivitis, viral | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Herpetic lid and corneal lesion | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Iritis | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | posterior vitreous detachment | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Pyogenic Granuloma | 1 Participants |
| Treatment of Myopia | Safety- Adverse Events | Retained tissue, small | 2 Participants |
| Treatment of Myopia | Safety- Adverse Events | Difficult lenticule removal with tissue damage | 2 Participants |
Primary
Safety- Contrast Sensitivity
Number of participants who increased, remained the same, and decreased in contrast sensitivity. There are 4 different frequencies (1.5, 3.0, 6.0, and 12.0) which will be tested and are more difficult to detect as the frequency number increases.
Time frame: 12 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment of Myopia | Safety- Contrast Sensitivity | Gained at greater than or equal to 2 frequencies | 72 Participants |
| Treatment of Myopia | Safety- Contrast Sensitivity | No change | 232 Participants |
| Treatment of Myopia | Safety- Contrast Sensitivity | Loss at greater than or equal to 2 frequencies | 5 Participants |
Primary
Safety- Induced Manifest Refractive Astigmatism
Number of participants with an increase of astigmatism of greater than 2.00 D cylinder from the preoperative values. Target is less than 5% of participants.
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment of Myopia | Safety- Induced Manifest Refractive Astigmatism | 0 Participants |
Primary
Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA)
1. Number of participants with worse than 20/40 visual acuity with a preoperative BSCVA (Best Spectacle Corrected Visual Acuity) 20/20 or better. Target is less than 1% of study participants. 2. Less than 5% of participants with BCVA loss ≥ 2 lines
Time frame: 12 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment of Myopia | Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA) | BSCVA worse than 20/40 if 20/20 or better preopera | 0 Participants |
| Treatment of Myopia | Safety- Preservation of Best-Spectacle Corrected Visual Acuity (BSCVA) | Loss of ≥ 2 lines BSCVA | 0 Participants |
Primary
Stability Criteria- Change Between Visits Within 0.50 Diopter (D)
Number of participants with a change in postoperative refraction within 0.50 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.
Time frame: 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment of Myopia | Stability Criteria- Change Between Visits Within 0.50 Diopter (D) | 317 Participants |
Primary
Stability Criteria- Change Between Visits Within 1.00 Diopter (D)
Number of participants with a change in postoperative refraction within 1.00 D between the 3 and 6 month visits. Stability was identified at the 6 month visit for the study.
Time frame: 6 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment of Myopia | Stability Criteria- Change Between Visits Within 1.00 Diopter (D) | 327 Participants |
Secondary
Safety- Patient Symptoms
A standardized quality of vision (QoV) questionnaire was used in the study. A score is generated and was used to compare the results from baseline to the 12 month visit. Number of participants who improved, stayed the same, or worsened with regards to the frequency, severity, and bothersomeness of symptoms are reported.
Time frame: 12 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Treatment of Myopia | Safety- Patient Symptoms | Bothersome | worse | 79 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Bothersome | same | 119 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Bothersome | improved | 111 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Frequency | same | 71 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Frequency | improved | 122 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Severity | worse | 93 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Severity | same | 95 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Severity | improved | 121 Participants |
| Treatment of Myopia | Safety- Patient Symptoms | Frequency | worse | 116 Participants |